Rate My Professor John Misasi

John Misasi, MD, serves as Assistant Professor of Virology, Immunology, and Microbiology at Boston University Chobanian & Avedisian School of Medicine and Adjunct Clinical Instructor in the Department of Pediatrics. He received his MD from the State University of New York Upstate Medical University and BS from Boston University, followed by pediatric residency training at New York University and fellowship in Pediatric Infectious Diseases at Boston Children’s Hospital.

In late 2023, Dr. Misasi joined the faculty of Boston University’s National Emerging Infectious Diseases Laboratories. His prior appointments include Instructor in Pediatrics at Boston Children’s Hospital and Harvard Medical School, as well as Staff Clinician and Assistant Research Clinician at the NIH Vaccine Research Center, where he was Chief of the Yeast Engineering Technology and Immunobiology Core. Dr. Misasi’s research centers on host factors for filovirus entry, antibody discovery and protein engineering to combat lethal infections from Ebola, Lassa, HIV, RSV, SARS-CoV-2, and MPOX viruses. He investigates mechanisms of antibody binding, neutralization, and viral immune evasion, alongside correlations between antibody quality, disease outcomes, and enduring immunity. His efforts target lifecycle vulnerabilities of pediatric respiratory viruses and high-containment pathogens to advance structure-based vaccine and therapeutic strategies.

With 42 publications, notable works include “A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo” (2024), “Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D Vaccine” (2026), “Exploring host-virus interaction to improve immunotherapy against Ebola virus” (2023), “Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody” (2016), and “Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection” (2011). Dr. Misasi is an inventor on multiple antibody patents and contributed to mAb114 (ansuvimab), the FDA-approved Ebola therapy.